Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Takeda Pharmaceutical CO Ltd (TAK)

Takeda Pharmaceutical CO Ltd (TAK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates

Seattle Genetics (SGEN) betters loss estimates and rides high on revenue beat in Q2.

MRK : 81.39 (-1.57%)
SGEN : 75.07 (-2.05%)
RHHBY : 33.6401 (-2.41%)
TAK : 17.38 (-0.11%)
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or "the Company")...

SHPG : 179.20 (+4.10%)
TKPYY : 16.5900 (-0.90%)
TAK : 17.38 (-0.11%)
J&J Submits BLA for Subcutaneous Formulation of Darzalex

Johnson & Johnson (JNJ) submits a BLA to the FDA, seeking approval for a subcutaneous formulation of its multiple myeloma drug.

CELG : 90.20 (-0.78%)
JNJ : 130.31 (-1.33%)
RHHBY : 33.6401 (-2.41%)
TAK : 17.38 (-0.11%)
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or "the Company")...

SHPG : 179.20 (+4.10%)
TKPYY : 16.5900 (-0.90%)
TAK : 17.38 (-0.11%)
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or "the Company")...

SHPG : 179.20 (+4.10%)
TKPYY : 16.5900 (-0.90%)
TAK : 17.38 (-0.11%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK

Pomerantz LLP is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or the "Company") (NYSE: TAK). Such investors are advised to contact Robert S. Willoughby...

TKPYY : 16.5900 (-0.90%)
TAK : 17.38 (-0.11%)
Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status

The FDA grants orphan drug designation to Arcturus Therapeutics' (ARCT) candidate, ARCT-810 for treating patients with ornithine transcarbamylase deficiency, the most common urea cycle disorder.

RARE : 62.10 (-0.58%)
JNJ : 130.31 (-1.33%)
ARCT : 10.77 (+13.49%)
TAK : 17.38 (-0.11%)
J&J's Darzalex Gets FDA Nod for First-Line Multiple Myeloma

Johnson & Johnson's (JNJ) label expansion application, seeking approval for Darzalex+Revlimid to treat transplant ineligible newly diagnosed patients with multiple myeloma, receives FDA approval.

CELG : 90.20 (-0.78%)
JNJ : 130.31 (-1.33%)
RHHBY : 33.6401 (-2.41%)
TAK : 17.38 (-0.11%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK

Pomerantz LLP is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or the "Company") (NYSE: TAK). Such investors are advised to contact Robert S. Willoughby...

TKPYY : 16.5900 (-0.90%)
TAK : 17.38 (-0.11%)
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or "the Company")...

SHPG : 179.20 (+4.10%)
TKPYY : 16.5900 (-0.90%)
TAK : 17.38 (-0.11%)
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or "the Company")...

SHPG : 179.20 (+4.10%)
TKPYY : 16.5900 (-0.90%)
TAK : 17.38 (-0.11%)
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Takeda Pharmaceutical Company Limited - TAK

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Takeda Pharmaceutical Company Limited (NYSE: TAK) resulting from...

SHPG : 179.20 (+4.10%)
TKPYY : 16.5900 (-0.90%)
TAK : 17.38 (-0.11%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK

Pomerantz LLP is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or the "Company") (NYSE: TAK). Such investors are advised to contact Robert S. Willoughby...

TKPYY : 16.5900 (-0.90%)
TAK : 17.38 (-0.11%)
AbbVie Announces Lifting of FDA's Partial Hold on CANOVA Study

AbbVie (ABBV) receives encouraging news as FDA lifts partial clinical hold on a late-stage study evaluating Venclexta in relapsed/refractory multiple myeloma.

CELG : 90.20 (-0.78%)
ABBV : 68.54 (+0.42%)
RHHBY : 33.6401 (-2.41%)
TAK : 17.38 (-0.11%)
Verastem Up on Positive Data From Early-Stage Copiktra Study

Verastem (VSTM) presents encouraging data from an early-stage study evaluating its recently approved drug, Copiktra, for treating peripheral T-cell lymphoma.

MRK : 81.39 (-1.57%)
INFI : 1.61 (-2.42%)
VSTM : 1.43 (-10.06%)
TAK : 17.38 (-0.11%)
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Takeda Pharmaceutical Company Ltd. (TAK)

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Takeda Pharmaceutical Company Ltd. ("Takeda" or the "Company") (NYSE: TAK). Such...

TKPYY : 16.5900 (-0.90%)
TAK : 17.38 (-0.11%)
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Takeda Pharmaceutical Company Ltd. (TAK)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Takeda Pharmaceutical Company Ltd. ("Takeda" or the "Company") (NYSE: TAK). Such investors are encouraged...

TKPYY : 16.5900 (-0.90%)
TAK : 17.38 (-0.11%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK

Pomerantz LLP is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or the "Company") (NYSE: TAK). Such investors are advised to contact Robert S. Willoughby...

TKPYY : 16.5900 (-0.90%)
TAK : 17.38 (-0.11%)
Kamada (KMDA) to Report Q1 Earnings: What's in the Cards?

Kamada (KMDA) is expected to provide updates on pipeline candidates during the first-quarter earnings call.

KMDA : 5.94 (-0.50%)
LOGC : 12.70 (-3.57%)
CTST : 2.77 (-5.46%)
TAK : 17.38 (-0.11%)
Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y

Nektar's (NKTR) earnings and sales beat estimates in the first quarter. The company is progressing well with its pipeline candidates.

GILD : 65.04 (-3.23%)
BMY : 43.33 (-1.63%)
NKTR : 31.97 (-0.31%)
TAK : 17.38 (-0.11%)

Van Meerten Stock Picks

Leading Economic Indicator ALERT!
I very closely follow the Conference Board's Leading Economic Indicators.
IVV -1.75
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar